Intravitreal Nesvacumab (Anti-Angiopoietin-2) Plus Aflibercept in Neovascular AMD: Phase 2 ONYX Randomized Trial

MLA

Jeffrey S. Heier, et al. “Intravitreal Nesvacumab (Anti-Angiopoietin-2) Plus Aflibercept in Neovascular AMD: Phase 2 ONYX Randomized Trial.” Journal of VitreoRetinal Diseases, vol. 7, Dec. 2022, pp. 8–15. EBSCOhost, https://doi.org/10.1177/24741264221126061.

APA

Jeffrey S. Heier, Allen C. Ho, David S. Boyer, Karl Csaky, Robert Vitti, Lorah Perlee, Karen W. Chu, Friedrich Asmus, Sergio Leal, Oliver Zeitz, Yenchieh Cheng, Thomas Schmelter, & David M. Brown. (2022). Intravitreal Nesvacumab (Anti-Angiopoietin-2) Plus Aflibercept in Neovascular AMD: Phase 2 ONYX Randomized Trial. Journal of VitreoRetinal Diseases, 7, 8–15. https://doi.org/10.1177/24741264221126061

Chicago

Jeffrey S. Heier, Allen C. Ho, David S. Boyer, Karl Csaky, Robert Vitti, Lorah Perlee, Karen W. Chu, et al. 2022. “Intravitreal Nesvacumab (Anti-Angiopoietin-2) Plus Aflibercept in Neovascular AMD: Phase 2 ONYX Randomized Trial.” Journal of VitreoRetinal Diseases 7 (December): 8–15. doi:10.1177/24741264221126061.